Multiple sclerosis (MS), characterized by chronic inflammation, demyelination, and axonal damage, is a complicated neurological disease of the human central nervous system. Recent interest in adipose stromal/stem cell (ASCs) for the treatment of CNS diseases has promoted further investigation in order to identify the most suitable ASCs. To investigate whether MS affects the biologic properties of ASCs and whether autologous ASCs from MS-affected sources could serve as an effective source for stem cell therapy, cells were isolated from subcutaneous inguinal fat pads of mice with established experimental autoimmune encephalomyelitis (EAE), a murine model of MS. ASCs from EAE mice and their syngeneic wild-type mice were cultured, expanded, and characterized for their cell morphology, surface antigen expression, osteogenic and adipogenic differentiation, colony forming units, and inflammatory cytokine and chemokine levels in vitro. Furthermore, the therapeutic efficacy of the cells was assessed in vivo by transplantation into EAE mice. The results indicated that the ASCs from EAE mice displayed a normal phenotype, typical MSC surface antigen expression, and in vitro osteogenic and adipogenic differentiation capacity, while their osteogenic differentiation capacity was reduced in comparison with their unafflicted control mice. The ASCs from EAE mice also demonstrated increased expression of pro-inflammatory cytokines and chemokines, specifically an elevation in the expression of monocyte chemoattractant protein-1 and keratin chemoattractant. In vivo, infusion of wild type ASCs significantly ameliorate the disease course, autoimmune mediated demyelination and cell infiltration through the regulation of the inflammatory responses, however, mice treated with autologous ASCs showed no therapeutic improvement on the disease progression.
Citation: Zhang X, Bowles AC, Semon JA, Scruggs BA, Zhang S, Strong AL, et al. (2014) Transplantation of Autologous Adipose Stem Cells Lacks Therapeutic Efficacy in the Experimental Autoimmune Encephalomyelitis Model. PLoS ONE 9(1): e85007. https://doi.org/10.1371/journal.pone.0085007
Editor: Ralf Andreas Linker, Friedrich-Alexander University Erlangen, Germany
Received: April 13, 2013; Accepted: November 27, 2013; Published: January 21, 2014
Copyright: © 2014 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for this study was provided by Tulane University and the Pennington Biomedical Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Multiple sclerosis (MS), characterized by chronic inflammation, demyelination, and axonal damage, is a complicated neurological disease of human central nervous system (CNS) and is the most common neurological disease in young adults among 20–40 years old –. So far, immunotherapies are the most commonly used treatment approaches for MS, ranging from nonselective immunosuppressor, such as interferon-β or glatiramer acetate, to highly specific immune interventions such as the monoclonal antibody natalizumab against the cell adhesion molecule α4-integrin , . Although the existing treatments for MS partially alleviate symptoms, they do not halt the ongoing progression of neurodegeneration. Experimental autoimmune encephalomyelitis (EAE), which exhibits many clinical and histological features of MS, is the most widely used and best characterized experimental animal model for MS. EAE is usually induced by immunization with myelin proteins such as myelin oligodendrocyte glycoprotein (MOG) and adjuvants, which results in the immune system mediated destruction of the myelinated CNS , .
Bone marrow-derived mesenchymal stem cell (BM-MSC) based cell therapy for EAE have been extensively studied – because of the BM-MSCs' self-renewal ability, potential of differentiation into multiple lineages, and immunomodulatory effects through the secretion of cytokines and chemokines. Although bone marrow remains the main source for mesenchymal stem cells in clinical trials, adipose tissue is an ideal source due to its abundance, easy accessibility, and the feasibility of harvesting by a minimally invasive procedure. Moreover, large amounts of cells can be isolated from the adipose tissue, yielding 100–500 fold higher stem cells per tissue volume than bone marrow , . Meanwhile, adipose-derived stromal/stem cells (ASCs) have similar self-renewal abilities, surface epitopes, growth kinetics, and cytokine expression profiles as their counterparts from bone marrow –.
Studies have been performed using ASC or genetically-modified ASC therapy for the treatment of EAE , . The results from these studies clearly demonstrated that ASC-based cell therapy could ameliorate the disease and enhance anti-inflammatory responses. Consequently, it is important to consider the question of whether the outcome of ASCs infusion differs when cells are sourced from EAE afflicted or unaffected controls. It is presumed that autologous ASC transplantation will have lower rates of post-transplant complications and lower risk of transmission of infectious diseases compared to allogeneic transplantation. Moreover, although allogeneic MSC therapy has been used for the treatment of various diseases, such as Graft versus host disease, some studies have shown that allogeneic MSCs transplantation could be rejected by the host immune system . In contrast, autologous transplantation of stem cells does not have issues related to donor availability or risk of histo-incompatibility. Thus, autologous ASCs offer numerous theoretical advantages from regulatory, histocompatibility, and immunological perspectives .
In the in vitro studies presented here, ASCs were isolated from diseased EAE mice, cultured, expanded, and characterized by means of flow cytometry, differentiation assays, colony forming unit assays, and real-time PCR to determine whether the EAE alters ASCs properties relative to those derived from unafflicted control mice. In vivo, ASCs from the EAE mice, transplanted back in the EAE mouse model, were assessed for their therapeutic effects on delaying the disease course, ameliorating the demyelination and modulation of the immune responses.
Materials and Methods
EAE induction and treatment
All the protocols and experimental procedures were approved by the Institutional Animal Care and Use Committee at Tulane University. Female C57Bl/6 mice, 6 to 8 weeks old, were purchased from Charles River Laboratories (Wilmington, MA), and allowed 7 days to acclimate before the start of the study. Chronic EAE was induced in the female C57Bl/6 mice by subcutaneous immunization with MOG35–55 (Anaspec, San Diego, CA), which was emulsified in Complete Freund's adjuvant with 8 mg/ml of Mycobacterium tuberculosis H35RA (Difco, Detroit, MI) in 1∶1 ratio, and 100 µl (100 ng) of emulsified MOG35–55 was injected sub-cutaneously at each side of the base of the tail respectively. Each mouse also received 100 µl (200 ng) of pertussis toxin (List Biological Laboratories, Campbell, CA) by intraperitoneal (i.p.) injection, and the injection of toxin was repeated 2 days later. Concurrently, a total of 1×106 ASCs from the EAE mice (EAEASC) or from unafflicted control mice (WtASC) suspended in 100 µl total volume of HBSS were injected into the mice intraperitoneally. Negative control animals consisted of EAE-induced mice injected with equal volumes of vehicles only (HBSS), and positive control animals were non-EAE-induced normal mice which only received one i.p. injection of the equal volume of HBSS. The experiments were conducted on three independent cohorts with 20 mice total for each treatment and control group.
Isolation and culture of adipose-derived stem cells
The subcutaneous inguinal fat pads were isolated from the Hank's balanced salt solution (HBSS) (Life Technologies, Grand Island, NY)-treated EAE mice and HBSS treated normal non-induced mice on post EAE disease induction (PDI) day 30, rinsed with HBSS to remove blood and hair contamination, and digested with 0.1% collagenase type 1 solution (Life Technologies) for approximately 4 hours at 37°C under mild agitation. The digested adipose tissues were then filtered through a 70-µm nylon mesh cell strainer (BD Biosciences, Bedford, MA), and centrifuged at 500×g for 10 minutes at room temperature (RT). The pellets were re-suspended and cultured in the cell culture medium (CCM), made of DMEM∶F12 (Life Technologies) supplemented with 10% fetal bovine serum(FBS, Atlanta Biologicals, Atlanta, GA), 2 mM L-glutamine (Life Technologies), and 1% antibiotic/antimycotic (Penicillin/streptomycin/amphotericin, Life Technologies). After 24 hours, the non-adherent cells were washed with phosphate buffered saline (PBS, Life Technologies) and fresh CCM were added. When cells reached 70–80% confluence, the passage 0 cells were lifted with 0.25% trypsin/1 mM EDTA (Life Technologies) and sub-cultured at 100 cells/cm2 in CCM on 145 cm2 tissue culture dishes (Nalge Nunc International, Rochester, NY). Media was replaced every 3–4 days, and cells were routinely passaged when they reached 70% confluence unless otherwise noted. For all experiments, ASC lines between passages 3–5 were used.
The following antibodies were used to check the cell surface marker profiles of EAEASCs and WtASCs: CD29, CD34, CD31, CD45, CD11b, and Sca1 (stem cell antigen-1). All of the antibodies were purchased from BD Biosciences. The ASCs were cultured, trypsinized, pelleted, and re-suspended in 500 µl PBS. The cells were incubated with the antibodies for 30 minutes at RT, then washed with PBS, and analyzed by Cytomics FC500 (Beckman Coulter, Brea, CA). The results were analyzed with CXP analysis software (Beckman Coulter).
ASCs at passage 5 were cultured on 6-well Nunc plates (Nalge Nunc International) to approximately 90% confluence before adipogenic and osteogenic differentiation media were added. Adipogenic differentiation medium was made with CCM supplemented with 5 µg/ml insulin, 50 µM indomethacin, 1 µM dexamethasone and 0.5 µM 3-isobutyl-1-methylxanthine (all media supplements were purchased from Sigma, St Louis, MO). Osteogenic differentiation medium was made with CCM supplemented with 1 nM dexamethasone, 20 mM β-glycerolphosphate, 50 µM L-ascorbic acid 2-phosphate sesquimagnesium salt, and 50 ng/ml L-thyroxine sodium pentahydrate. Media were changed twice per week for 3 weeks. For adipogenic differentiation, the cells were washed with PBS, fixed with 10% formalin (Sigma) for 20 minutes at RT, washed again with PBS, stained with Oil Red-O (Sigma) for 20 minutes at RT, and washed with PBS until wash was clear. For the detection of osteogenesis, the cells were washed with PBS, fixed with 10% formalin for 20 minutes at RT, washed with deionized (DI) water, stained with Alizarin Red (Sigma) for 20 minutes at RT, and washed with DI water until wash was clear. Images were acquired at 10× for adipogenic differentiation and 4× for osteogenic differentiation on Nikon Eclipse TE200 (Melville, NY) with Nikon Digital Camera DXM1200F using the Nikon ACT-1 software version 2.7.
The levels of adipogenic and osteogenic differentiation were also quantified. For the quantification of adipogenic differentiation, the accumulated lipids were eluted with isopropanol after images were captured. The amount of Oil Red O was measured by recording the optical density (OD) of the solution at 584 nm. The results were normalized to the protein content of the samples with the BCA assay (Thermo Scientific, Rockford, IL). For the quantitative osteogenesis assay, the cells were de-stained, after images were taken, with 10% cetylpyridinium chloride (Sigma) for 30 minutes at RT. The amount of Alizarin Red was determined by measuring the OD of the solution at 584 nm. The results were normalized to the protein content of the samples.
Colony forming unit assay
ASCs at passage 5 were seeded onto 56.7 cm2 Nunc cell culture plates (Nalge Nunc International) in 5 replicates at a total of 100 cells per plate. Growth media was changed every 3–4 days. After 14 days, the cells were washed with PBS, stained with 3% crystal violet in 100% methanol for 30 minutes at RT, and then washed with DI water at least 3 times to remove excess dye. All colonies greater than 2 mm in diameter were counted. The cells were de-stained with methanol, after images were taken, for 40 minutes under mild agitation at RT. The amount of staining was measured by recording the optical density (OD) of the solution at 584 nm, and the arbitrary unit was defined as the OD divided by the pre-counted colony number.
Real-time quantitative PCR
Cells at passage 5 were seeded onto 145 cm2 tissue culture dishes with a density of 1×106 cells/dish, and incubated for 24 hours. The cells were then trypsinized and pelleted for extraction total cellular RNA using RNeasy Mini Kit (Qiagen, Valencia, CA). The concentration and purity of the RNA were assessed by Nanodrop 2000 spectrophotometer (Thermo Scientific). RNA was first treated with DNase (Life Technologies), and first strand cDNA syntheses were performed using iScript cDNA Synthesis kit (Biorad, Hercules, CA). Real-time PCR was performed to analyze the mRNA levels for mouse cytokines and chemokines, specifically TNFα, IL-6, MCP-1, MIP-1α, RANTES, KC, MIP-2α and VEGF. PCR reactions were performed using CFX96 Real Time System (Biorad) in a total volume of 20 µl containing 10 µl Taqman mastermix (Applied Biosystems, Foster City, CA), 1 µl primer and probe mix (Applied Biosystems), 7 µl dH2O and 2 µl template. Reaction mixtures were incubated at 50°C for 2 minutes and 95°C for 10 minutes, and reactions were allowed to proceed via 40 cycles of melting at 95°C for 15 seconds, annealing and extension at 60°C for 1 minute. The housekeeping gene β-actin (UniGene: Mm328431) was used as internal reference. Quantification was calculated using ΔΔCt method .
Mice were monitored daily for clinical signs of EAE by three independent investigators. Clinical scores were based on a scale of 0–5 with a score of 0 indicating no disease; 1-limp tail (loss of tail tone); 2-limp tail and hind limb weakness; 3-limp tail and partial hind limb paralysis; 4-limp tail and complete hind limb paralysis; and 5- moribund or dead.
Tissue Processing and Histological Analysis
On PDI day 30, animals were euthanized by exposure to CO2 and perfused with sterile PBS. Spinal cords were removed, fixed in 10% formalin (Thermo Scientific) and then embedded in paraffin. Sections were cut at 5 microns on a microtome and stained for Luxol Fast Blue/Crystal Violet (LFB, IHC World, Ellicott City, MD) and Hematoxylin and Eosin (H&E) for identification of intact myelin and infiltrating cells respectively. Histological images were collected on an ImageScope (Aperio, Vista, CA), and the LFB images were analyzed with Aperio Software. The quantification of the percentage of positivity was determined by the percentage of positive pixels divided by the total number of pixels in a given section. The H&E images were analyzed with Fiji/Image J software to quantify the number of total cells (i.e., cells ≥5 µm2) per field at 40× magnification . Quantification was performed on three sections per animal and three animals per group. Indices were normalized to the average value obtained in normal un-induced mice (set as 1).
Analysis of Spinal Cord Lesions
Spinal cord sections were prepared 5 microns thick and stained with LFB and H&E for myelination and infiltrating cell detection, respectively. Each section was analyzed using Aperio ImageScope for quantitative measures of lesions. Lesion detection was determined by dense areas of both LFB and H&E stain containing high concentrations of infiltrating cells located in the ventral and lateral columns of the spinal cord. Lesions were manually delineated in H&E stained sections and subsequently analyzed using modified positive pixel count algorithms specific for H&E stained sections.
Lesions were scored according to categories established in Niimi et al., 2013 . Briefly, Grade 1- leptomeningeal cell infiltration, Grade 2- mild perivascular cuffing, Grade 3- moderate perivascular cuffing, Grade 4 – extensive perivascular cuffing.
Tissue sections (paraffin-embedded) were warmed on a heating platform at 57°C for 30 minutes prior to deparaffinization. For deparaffinization, all slides were submerged in HistoChoice (Amresco, Solon, OH) twice for 5 min, 100% ethanol twice for 2 min, 95% ethanol twice for 2 min, 70% ethanol for 2 min, 50% ethanol for 2 min, and DI water twice for 2 min. The deparaffinized slides were submerged in citrate buffer pH 6.0 (10 mM) and heated for 30 min in a steamer. After cooling, the slides were washed for 5 min in 1× PBS and subsequently washed with PBS-FSG-Tx-100 (10% v/v 10× PBS, 0.2% v/v fish skin gelatin, and 0.1% v/v Triton x-100) for 5 min before incubation for 1 h in a humidified chamber at RT with blocking solution, which consisted of 10% normal goat serum (NGS) in PBS-FSG (10% v/v 10× PBS and 0.2% v/v fish skin gelatin). The primary antibody to astrocytes (GFAP; 1∶200, Sigma: C9205 Ms IgG1), CD3 (1∶200, Abcam, Cambridge, MA), CD11b (1∶200, eBiosciences, San Diego, CA), CD45 (1∶200, Invitrogen, Grand Island, NY) was diluted in 10% NGS solution and applied to appropriate experimental sections for overnight incubation in a humidified chamber at 4°C. Control slides were treated with secondary antibody-only (2° only). Following incubation, the slides were washed in PBS-FSG-Tx-100 and PBS-FSG, each for 10 min. The sections stained with anti-GFAP were then incubated in a humidified chamber at RT for 1 hour with the secondary antibody (e.g., anti-rat, with Alexa 594) in 10% NGS solution. Slides were then washed twice in PBS-FSG-Tx-100 and once in PBS-FSG. The slides were mounted with mounting medium with DAPI (Vector Laboratories, INC. Burlingame, CA), and imaged using a deconvolution microscope. Slides, stained with anti-CD3, CD11b, and CD45, were incubated with HRP-conjugated secondary antibodies (Abcam, Cambridge, MA) for 1 hour at room temperature then processed with DAB peroxidase substrate kit (Vector Laboratories, Inc., Burlingame, CA) followed by Hematoxylin (Invitrogen, Grand Island, NY) counterstain. Slides were washed, dehydrated, and mounted with Permount (FisherChemicals, Fair Lawn, NJ).
Spinal cord sections analyzed with ImageScope were used to identify CD3, CD11b, and CD45-positive cells within the manually delineated lesions for each group. Using the positive pixel count algorithm, the frequency of each antigen-specific cell infiltrating within each lesion was determined by the number of strong positive pixels (Nsp) divided by the total number of pixels (NTotal) multiplied by 100.
Serum ELISA assay
On PDI day 30, blood samples were collected from each treatment and control group to analyze circulating levels of cytokines TNFα, IL-12 and IL-17 by ELISA assay (Invitrogen, Grand Island, NY) according to the manufacturer's instructions. The concentration of each cytokine was calculated based on the standard curve generated.
Data sets were analyzed by the Kruskal-Wallis non-parametric one-way analysis of variance (ANOVA), followed by post-hoc Dunnet multiple comparison tests versus the respective control group. For pair-wise comparisons, the F-test was used to determine whether a given pair of population variances was equal (α<0.05). This information was then used in designating the appropriate t-tests (typically heteroscedastic) to perform for comparing the means of population pair, with significance defined as P<0.05. All values were reported as mean ± SD except for the clinical scoring where the values were reported as means ± SEM.
Flow cytometric analysis of EAEASC
The cell morphology of EAEASCs was consistent with that of the ASCs from the unafflicted control mice, which were fibroblast-like in appearance (data not shown). EAEASCs and WtASCs were analyzed by flow cytometry, and their cell surface antigens were similar (Fig. 1A). Both cell types were positive for CD29 and ScaI, while they were negative for endothelial (CD31), hematopoietic markers (CD45 and CD34) and macrophage marker CD11b. The sizes of both cell types were also analyzed based on the forward scatter signals of flow cytometry. As shown in Figure 1B, the cell size of EAEASCs versus WtASCs was not significantly different (t-test, P>0.05).
A) Cells were analyzed by flow cytometry for MSC surface markers CD29, Sca1; hematopoietic markers CD34 and CD45; phagocytic lineage marker CD11b; and endothelial marker CD31. Gray filled: isotype control; gray line: WtASCs; black line: EAEASCs. B) Cell size based on forward scatter signal of flow cytometry (P = 0.26, t-test, n = 7).
Differentiation assays for EAEASC
EAEASCs and WtASCs were cultured in osteogenic and adipogenic differentiation medium for 3 weeks to test their lineage differentiation efficiency. On day 21, the ASCs were stained with Alizarin Red to assess bone mineralization, and with fresh Oil Red O for lipid droplets. Both EAEASCs and WtASCs efficiently differentiated into osteocytes and adipocytes (Fig. 2). However, as shown in Figure 2A, the EAEASCs had reduced osteogenic differentiation capacity when compared to the WtASCs. Quantification of the differentiation levels of both cell types (Fig. 2B) further demonstrated that WtASCs (OD ratio = 15.39±2.88) could differentiate into osteocytes to a much greater degree than EAEASCs (OD ratio = 2.03±0.35) (t-test, P<0.05) over the period of the assay. Quantification of adipocyte differentiation indicated that EAEASCs (OD ratio = 0.90±0.11) had a similar differentiation capacity as WtASCs (OD ratio = 0.80±0.14) (t-test, P>0.05). The graph in Figure 2B represents the ratios of OD of differentiated cells normalized to control cells. Real-time PCR analysis of osteogenic markers alkaline phosphatase and runt-related transcription factor 2 in differentiated EAEASCs and WtASCs showed that there was no difference in these two transcriptional factors between the two cell types (data not shown).
A) Differentiated EAEASCs and WtASCs. Cells were incubated in adipogenic or osteogenic differentiation media for 21days and stained, respectively, with Oil Red O and Alizarin Red. For osteogenic differentiation, images were collected at 4× magnification. For adipogenic differentiation, images were obtained at 10× magnification. B) Quantification of osteogenesis and adipogenesis. For the quantitation of osteogenesis, the cells were de-stained with 10% cetylpyridinium chloride after stained with Alizarin Red. For the quantitation of adipogenesis, the cells were de-stained with isopropanol. Optical density (OD) was measured at 584 nm and normalized to protein content. The bar graph represents the ratio of normalized OD of differentiated cells and normalized OD of control cells. # means P<0.05 vs WtASCs (t-test, n = 3).
Colony forming unit assay
EAEASCs and WtASCs were assessed for their self-renewal ability by the colony forming unit (CFU) assay. All colonies greater than 2 mm in diameter were counted. The results indicate that EAEASCs (27.8±11.12 CFU) have the same self-renewal capacity as WtASCs (35.2±8.20 CFU) (Fig. 3A) (t-test, P>0.05). However, the colony diameter or area of WtASC was much larger and the intensity of the crystal violet stain was more intense when compared to EAEASCs (Fig. 3B). Elution of the stain with methanol, and determination of the optical density (OD) of the solution at 584 nm were performed to quantitate these differences. An arbitrary unit was defined as the OD divided by the pre-counted colony numbers. As shown in Figure 3C, WtASCs presented a much higher arbitrary CFU (4.51±0.73%) than EAEASCs (2.09±0.43%) (t-test, P<0.05).
A total of 100 cells were plated on 56.72 Nunc cell culture plates and incubated for 14 days. Cells were stained with 3% crystal violet, and colonies 2 mm or larger in diameter were counted. # means P<0.05 vs WtASCs (t-test, n = 5).
Cytokine and Chemokine expression of EAEASC
Both cell types were cultured overnight, trypsinized, and analyzed by real-time PCR to determine the mRNA expression levels of various cytokines and chemokines (TNFα, IL-6, MCP-1, MIP-1α, RANTES, KC, MIP-2α and VEGF). EAEASC demonstrated increased expression of MCP-1 and KC, and reduced expression of VEGF (t-test, P<0.05). There is no statistical difference between the two cell types related to their expression of TNFα, IL-6, MIP-1α, RANTES, and MIP-2α (Fig. 4) (t-test, P>0.05).
Both cell types were cultured overnight, trypsinized, and analyzed by real-time PCR to determine the expression levels of various cytokines and chemokines TNFα, IL-6, MCP-1, MIP-1α, RANTES, KC, MIP-2α and VEGF. # means P<0.05 EAEASCs vs WtASCs (t-test, n = 3).
Therapeutic effects of EAEASC on MOG35–55 induced chronic EAE
The therapeutic potential of EAEASCs was investigated in the EAE model. EAEASCs and WtASCs were administrated into the EAE mice by i.p. injection simultaneously on the day of disease induction. Our previous work (unpublished data) demonstrated that ASCs derived from healthy mice could significantly ameliorate the disease course and autoimmune mediated demyelination. Consistent with these prior studies, infusion of WtASCs ameliorated the symptoms and delayed the disease progression in comparison to the HBSS-treated controls, resulting in a statistically significant reduction of cumulative disease scores (Fig. 5). Moreover, mice treated with WtASCs showed a delayed onset of disease when compared with those in the HBSS-treated control group (Fig. 5). However, animals infused with EAEASCs showed no therapeutic improvement on the disease progression, and the mice in this group had an earlier onset of disease than those in the HBSS-treated control group.
The clinical scores for the HBSS-treated (n = 20), EAEASC-treated (n = 20) and WtASC-treated (n = 20) EAE mouse groups were recorded daily for the duration of the study. WtASCs significantly reduced the clinical symptoms from PDI13 where the EAEASCs failed to mediate any therapeutic efficacy or improvement. # means P<0.01 vs HBSS-treated EAE group (post-hoc, n = 20); • means P<0.01 vs EAEASCs-treated EAE group (post-hoc, n = 20).
Histological and immunohistochemistry analysis on the spinal cord
Mice from the treatment and control groups were sacrificed on PDI day 30, and the lumbar spinal cords were stained with LFB and H&E for the assessment of demyelination and cell infiltration respectively. Quantification of demyelination by density analysis of LFB-stained spinal cord sections revealed a 22% decrease in myelin density in HBSS-treated EAE mice. Furthermore, EAEASC treatment showed no improvement in re-myelination and had the same myelin density reduction degree (29%) as the HBSS-treated EAE mice (Fig. 6) (post-hoc, P>0.05). In contrast, WtASC treated animals had less demyelination, with myelin densities similar to those mice in the normal control (post-hoc, P>0.05). For cell infiltration analysis, as shown in Figure 6, EAEASC treatment did not reduce the levels of cell infiltration and had the same number of cells infiltrated (67.6±13.3 cells per field) as the HBSS-treated EAE mice (68.2±9.21cells per field), while WtASC treatment (30.0±10.6 cells per field) significantly decreased the number of infiltrating cells present in the spinal cords compared to the HBSS-treated and the EAEASC treated mice (post-hoc, P<0.01). Immunohistochemistry staining for the assessment of the cellular composition of the infiltrates revealed that there was increased astrocyte population in the EAEASC treated and the HBSS-treated mice as compared to the WtASC treated and the normal control mice (Fig. 6), Moreover, CD3, CD11b and CD45 staining demonstrated that there were more T cell, macrophage and B cell infiltration in the EAEASC treated mice as compared to the WtASC treated ones (Fig. 7). As shown in Figure 7, lesion analysis of the spinal cords also revealed that the lesion number and size were significantly reduced in the WtASC treated mice when compared to the EAEASC treated and the HBSS-treated ones.
Spinal cords were collected at sacrifice from 3 mice per group. Each spinal cord was sectioned, mounted, and stained with luxol fast blue (LFB), H&E, and anti-GFAP for intact myelin, cell infiltration and astrocytes levels. Images were acquired at 4×, 40× and 10×magnification. The LFB stained sections (n = 3 mice; 3 sections/mouse) were quantified for the intensity of the blue staining using Aperio Software. The H&E stained sections (n = 3 mice; 3 sections/mouse) were quantified for the total cells per field using Fiji/Image J software. ## means P<0.01 EAEASCs-treated vs WtASCs-treated EAE group (post-hoc, n = 9); ** means P<0.01 EAEASCs-treated vs normal naïve mouse group (post-hoc, n = 9); ••means P<0.01 HBSS-treated vs WtASCs-treated EAE group (post-hoc, n = 9); ¥¥ means P<0.01 HBSS-treated vs normal naïve mouse group (post-hoc, n = 9).
Spinal cords were collected at sacrifice from 3 mice per group. Each spinal cord was sectioned, mounted, and stained with anti-CD3, CD11b, and CD45 followed by Hematoxylin counterstain for lesion size, number and cell infiltration analysis. # means P<0.05 vs EAEASC-treated EAE group (post-hoc, n = 9); & means P<0.05 vs HBSS-treated EAE group (post-hoc, n = 9).
Serum cytokine levels
ELISA Assays were used to investigate the TNFα, IL-12 and IL-17 cytokines levels in each treatment group. As illustrated in Figure 8, WtASC treatment significantly reduced the circulating levels of pro-inflammatory cytokines TNFα and IL-12 (post-hoc, P<0.05) when compared to HBSS-treated EAE mice. Furthermore, the levels of TNFα and IL-12 were similar to (TNFα, post-hoc, P>0.05) or even lower (IL-12, post-hoc, P<0.05) than those circulating in the normal mice. However, the EAE mice treated with EAEASC had serum TNFα and IL-12 levels indistinguishable from HBSS-treated EAE mice (post-hoc, P>0.05). The circulating level of IL-17 remained the same in all the treatment and control groups (ANOVA, P>0.05).
Sera from 5 mice per group at sacrifice were pooled and analyzed by ELISA to detect levels of TNF-α, IL-12, and IL-17. # means P<0.05 vs HBSS-treated EAE group (post-hoc, n = 5); • means P<0.05 vs EAEASCs-treated EAE group (post-hoc, n = 5); & means P<0.05 vs normal naïve mouse group (post-hoc, n = 5).
Transplantation of BM-MSCs from healthy syngeneic controls has demonstrated striking therapeutic effects and unique immuno-modulatory capacities when delivered early to EAE mice , . ASCs have similar properties to BM-MSCs, and have received increased attention in regenerative medicine and tissue engineering because of the abundance, easy accessibility of adipose tissues, and the feasibility of harvest cells by a minimally invasive procedure. Previous studies from our group  and other labs  have showed that intraperitoneal administration of ASCs derived from healthy mice could significantly ameliorate the disease course and autoimmune mediated demyelination through the regulation of the inflammatory responses. The data, showing milder disease symptoms with decreased number of inflammatory infiltrates and reduced demyelination, further confirmed the immune-modulatory effects of wild type ASCs. The results demonstrated that the therapeutic effect of WtASCs is due to the modulation of the inflammatory response associated with the tissue damage rather than tissue repair sustained by regeneration of damaged neurons and oligodendrocytes. The therapeutic benefits are related to immune suppression exerted by WtASCs as demonstrated in other studies , , .
In this paper, ASCs isolated from HBSS-treated EAE mice were cultured, analyzed in vitro, and intraperitoneally transplanted into EAE mice in vivo to investigate whether the disease altered the biology profiles of ASCs in vitro and the efficacy of autologous transplantation in vivo. The EAEASCs displayed all the characteristics that defined for MSCs in vitro. They are adherent to plastic surfaces, fibroblast-like and spindle shaped. The EAEASCs displayed the same characteristic surface markers. EAEASCs, like WtASCs, are positive for surface markers CD29 and ScaI, and negative for hematopoietic markers CD45, CD31, CD34 and macrophage marker CD11b. The EAEASCs could readily form single cell colonies, and differentiate into osteocytes and adipocytes when induced under proper media. However, the results showed that the osteogenic capacity of the EAEASCs was reduced as compared to the WtASCs (Fig. 2). The reason that EAEASCs have reduced osteogenic differentiation ability is unclear. There was no difference in osteogenic markers, such as alkaline phosphatase and runt-related transcription factor 2, in differentiated EAEASCs and WtASCs. Assessment of their inflammatory cytokine and chemokine profiles through real-time PCR demonstrated that the EAEASCs displayed a more pro-inflammatory profile with elevated expression of MCP-1 and KC as compared to the WtASCs. Studies have shown that chronic inflammation adversely affects bone formation , . The pro-inflammatory profile of EAEASCs may play a role in their reduced differentiation capacity along the osteogenic lineage.
Interestingly, the EAEASCs demonstrated a lack of therapeutic efficacy when transplanted back into the EAE mice in vivo. The data showed that the EAEASCs did not delay the disease time course, decrease the extent of demyelination or decrease inflammation (Fig. 5–8). It is not clear why EAEASCs lacked a therapeutic benefit when delivered for the treatment of EAE mice. However, when tested for in vitro cytokine and chemokine expression levels, EAEASCs increased expression of MCP-1 in comparison to the WtASCs. MCP-1 (known as chemokine C-C motif ligand 2 in systematic nomenclature) is one of the key chemokines that regulate the migration and infiltration of monocytes/macrophages . While constitutive expression of MCP-1 in healthy CNS is relatively low, it is present and plays a critical pathogenic role in mediating neuroinflammation in various diseases including MS and its EAE animal model –. The exact mechanism of MCP-1 action remains unclear, however, numerous studies – have recognized that MCP-1 modulates blood-brain barrier disruption and attraction of mononuclear leukocytes migration into the CNS. In rodents with EAE, MCP-1 expression is correlated with disease severity and parallels with disease onset , . MCP-1 synthesis inhibition by the compound bindarit resulted in the delay, prevention and attenuation of EAE disease , which further supports the widely proposed MCP-1 role in neuroinflammation. It seems that, although they were cultured and expanded in vitro under standard cell culture condition, the EAEASCs may have been irreversibly altered by the diseased pro-inflammatory microenvironment in vivo, which may contribute to the lack of EAEASC therapeutic efficacy.
To date, clinical trials for MS have not focused on the use of autologous cells, but have used heterologous donor cells , . Nevertheless, one study analyzed the characteristics of the BM-MSCs from MS patients in vitro, and it concluded that BM-MSCs from individuals with MS, compared to individuals without MS, displayed a normal phenotype and were similar in proliferation, in vitro differentiation potential and cell surface antigen expression . Four Phase 1 clinical trials for the treatment of MS using autologous BM-MSCs have been approved –. The preliminary data from these trials demonstrated promising data in terms of clinical parameters and immunological analysis . However, the early findings will require further validation with larger studies due to the limited number of the patients enrolled in the trials and the uncontrolled natures of the trials.
In conclusion, the ASCs from mice with EAE displayed a normal phenotype, typical MSC surface antigen expression, and in vitro osteogenic and adipogenic differentiation capacity; however, the degrees of osteogenesis and CFU formation were compromised relative to WtASC. Most importantly, the EAEASCs lost their therapeutic efficacy for the treatment of EAE mice in vivo, which may be due to the distinct pro-inflammatory secretory profile they developed in the setting of chronic neuroinflammation. Thus, autologous transplantation of ASCs for the treatment of the mouse model of EAE appears to lacking efficacy. While careful validation and experimental testing must be performed before any extrapolation is made based on the animal studies, the current work suggests that autologous ASCs from individuals with MS should be evaluated and compared extensively to allogeneic ASCs from healthy individuals prior to clinical trials.
We thank Alan Tucker in our flow cytometry core for his help with flow cytometry analysis, and Dina Gaupp and Claire Llamas in our Histology Core for performance of the histological staining for this study.
Conceived and designed the experiments: XZ. Performed the experiments: XZ. Analyzed the data: XZ. Contributed reagents/materials/analysis tools: BB. Wrote the paper: XZ. Helped perform the experiment: AB BS SZ AS. Helped analyze the data: AB. Helped design the experiment: JS. Helped edit the manuscript: AS JG BB.
- 1. Miller DH (2004) Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 1: 284–294.
- 2. Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2: 201–211.
- 3. Kieseier BC, Wiendl H, Hemmer B, Hartung HP (2007) Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 20: 286–293.
- 4. Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, et al. (2012) Transplantation of Placenta-Derived Mesenchymal Stem Cells in the EAE Mouse Model of MS. J Mol Neurosci
- 5. Baker D, Jackson SJ (2007) Models of Multiple Sclerosis. ACNR 6: 10–12.
- 6. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al. (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755–1761.
- 7. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, et al. (2008) Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65: 753–761.
- 8. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, et al. (2009) Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57: 1192–1203.
- 9. Rafei M, Birman E, Forner K, Galipeau J (2009) Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 17: 1799–1803.
- 10. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, et al. (2009) Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 182: 5994–6002.
- 11. Gordon D, Pavlovska G, Uney JB, Wraith DC, Scolding NJ (2010) Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol 69: 1087–1095.
- 12. Lanz TV, Opitz CA, Ho PP, Agrawal A, Lutz C, et al. (2010) Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev 19: 657–668.
- 13. Fraser JK, Wulur I, Alfonso Z, Hedrick MH (2006) Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 24: 150–154.
- 14. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, et al. (2009) Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27: 2624–2635.
- 15. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, et al. (2003) Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174: 101–109.
- 16. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T (2005) Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum 52: 2521–2529.
- 17. Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, et al. (2006) Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 99: 1285–1297.
- 18. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K (2006) Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24: 1294–1301.
- 19. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, et al. (2007) Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 212: 702–709.
- 20. Schäffler A, Büchler C (2007) Concise review: adipose tissue-derived stromal cells–basic and clinical implications for novel cell-based therapies. Stem Cells 25: 818–827.
- 21. Payne N, Dantanarayana A, Sun G, Moussa L, Caine S, et al. (2012) Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adh Migr 6.
- 22. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106: 4057–4065.
- 23. Gimble JM, Katz AJ, Bunnell BA (2007) Adipose-derived stem cells for regenerative medicine. Circ Res 100: 1249–1260.
- 24. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101–1108.
- 25. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9: 676–682.
- 26. Niimi N, Kohyama K, Matsumoto Y (2013) Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases. Neuropathology
- 27. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, et al. (2007) Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 61: 219–227.
- 28. Semon JA, Zhang X, Pandey AC, Alandete SM, Maness C, et al. (2013) Administration of murine stromal vascular fraction ameliorates chronic experimental autoimmune encephalomyelitis. Stem Cells Transl Med 2: 789–796.
- 29. Sela J, Applebaum J, Uretzky G (1986) Osteogenesis induced by bone matrix is inhibited by inflammation. Biomater Med Devices Artif Organs 14: 227–237.
- 30. Liu Y, Liu W, Hu C, Xue Z, Wang G, et al. (2011) MiR-17 modulates osteogenic differentiation through a coherent feed-forward loop in mesenchymal stem cells isolated from periodontal ligaments of patients with periodontitis. Stem Cells 29: 1804–1816.
- 31. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313–326.
- 32. Dawson J, Miltz W, Mir AK, Wiessner C (2003) Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 7: 35–48.
- 33. Mahad DJ, Ransohoff RM (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15: 23–32.
- 34. Ge S, Shrestha B, Paul D, Keating C, Cone R, et al. (2012) The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis. J Neuroinflammation 9: 171.
- 35. Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, et al. (1995) Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 155: 5769–5776.
- 36. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV (2003) Potential role of MCP-1 in endothelial cell tight junction ‘opening’: signaling via Rho and Rho kinase. J Cell Sci 116: 4615–4628.
- 37. Song L, Pachter JS (2004) Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res 67: 78–89.
- 38. Toft-Hansen H, Buist R, Sun XJ, Schellenberg A, Peeling J, et al. (2006) Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system. J Immunol 177: 7242–7249.
- 39. Yao Y, Tsirka SE (2011) Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J Cell Sci 124: 1486–1495.
- 40. Godiska R, Chantry D, Dietsch GN, Gray PW (1995) Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 58: 167–176.
- 41. Luo Y, Fischer FR, Hancock WW, Dorf ME (2000) Macrophage inflammatory protein-2 and KC induce chemokine production by mouse astrocytes. J Immunol 165: 4015–4023.
- 42. Liang J, Zhang H, Hua B, Wang H, Wang J, et al. (2009) Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 15: 2.
- 43. Freedman SM, Bar-Or A, Atkins LH, Karussis D, Frassoni F, et al. (2010) The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 16: 7.
- 44. Mallam E, Kemp K, Wilkins A, Rice C, Scolding N (2010) Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Multiple Sclerosis 16: 909–918.
- 45. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, et al. (2007) Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 4: 50–57.
- 46. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, et al. (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67: 1187–1194.
- 47. Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, et al. (2010) Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 227: 185–189.
- 48. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, et al. (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 11: 150–156.
- 49. Uccelli A, Laroni A, Freedman MS (2012) Mesenchymal stem cells as treatment for MS - progress to date. Multiple Sclerosis Journal 0: 1–5.